Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

4.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
4.1K
Lineage Commitment01:21

Lineage Commitment

4.5K
Commitment is the  process whereby stem cells:
4.5K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.3K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.3K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.

The journal of allergy and clinical immunology. In practice·2025
Same author

[Complex control of the source of infection in sepsis : Extracorporeal membrane oxygenation (ECMO) as a bridging concept for tracheal fistula repair in sepsis-associated ARDS].

Der Anaesthesist·2016
Same author

Strong and deep Atlantic meridional overturning circulation during the last glacial cycle.

Nature·2014
Same author

Construction of a solenoid used on a magnetized plasma experiment.

The Review of scientific instruments·2014
Same author

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.

Leukemia·2011
Same author

Cryoneurolysis for zygapophyseal joint pain: a retrospective analysis of 117 interventions.

Acta neurochirurgica·2011

Related Experiment Video

Updated: Mar 21, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K

Stem cell persistence in chronic myeloid leukemia.

M Deininger1

  • 1Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT, USA.

Leukemia Supplements
|May 14, 2016
PubMed
Summary

Tyrosine kinase inhibitors (TKIs) control chronic myeloid leukemia (CML) but do not eradicate CML stem cells. Future therapies may target synthetic lethality by inhibiting BCR-ABL and other pathways to eliminate these persistent cells.

Keywords:
chronic myeloid leukemiadisease persistencesynthetic lethalitytyrosine kinase inhibitor

More Related Videos

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL
06:41

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

1.5K
A Culture Method to Maintain Quiescent Human Hematopoietic Stem Cells
07:14

A Culture Method to Maintain Quiescent Human Hematopoietic Stem Cells

Published on: May 17, 2021

5.5K

Related Experiment Videos

Last Updated: Mar 21, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K
Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL
06:41

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

1.5K
A Culture Method to Maintain Quiescent Human Hematopoietic Stem Cells
07:14

A Culture Method to Maintain Quiescent Human Hematopoietic Stem Cells

Published on: May 17, 2021

5.5K

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have transformed chronic myeloid leukemia (CML) management, shifting it from a fatal diagnosis to a manageable chronic condition.
  • Emerging evidence indicates that TKIs are not curative, as CML stem cells persist during treatment due to their independence from BCR-ABL.
  • This persistence aligns with fundamental principles of CML pathogenesis, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To investigate the limitations of current TKI therapies in eradicating CML stem cells.
  • To explore underlying mechanisms of CML stem cell persistence.
  • To propose future therapeutic strategies for CML eradication.

Main Methods:

  • Review of existing literature on TKI therapy for CML.
  • Analysis of CML stem cell biology and dependence on BCR-ABL.
  • Conceptualization of synthetic lethality approaches for CML treatment.

Main Results:

  • TKIs effectively manage CML but fail to eliminate CML stem cells.
  • CML stem cells exhibit resistance to TKIs due to their non-addiction to BCR-ABL.
  • Fundamental CML pathogenesis principles explain stem cell persistence.

Conclusions:

  • Current TKI therapies are insufficient for CML cure due to persistent stem cells.
  • Eradication of CML stem cells is crucial for achieving a definitive cure.
  • Future CML treatment strategies should focus on synthetic lethality, combining BCR-ABL inhibition with targeting of other critical pathways to eliminate CML stem cells.